{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:31Z","timestamp":1789726291228,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-023-10375-6","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T11:02:10Z","timestamp":1702983730000},"page":"479-496","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1000-9319","authenticated-orcid":false,"given":"Magdi S.","family":"Yacoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2831-9796","authenticated-orcid":false,"given":"Tamer","family":"El-Nakhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-8620","authenticated-orcid":false,"given":"Elfatih A.","family":"Hasabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-3289","authenticated-orcid":false,"given":"Nahla","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5329-344X","authenticated-orcid":false,"given":"Karim","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6859-0364","authenticated-orcid":false,"given":"Kenzy H.","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8469-5019","authenticated-orcid":false,"given":"Mohamed S.","family":"Bakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6739-5690","authenticated-orcid":false,"given":"Maram","family":"Mohsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-2416","authenticated-orcid":false,"given":"Asmaa","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9514-5696","authenticated-orcid":false,"given":"Eslam","family":"Abdelazim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8077-5911","authenticated-orcid":false,"given":"Hossam T.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4978-2168","authenticated-orcid":false,"given":"Ziad","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0150-8917","authenticated-orcid":false,"given":"Ahmed","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2499-5570","authenticated-orcid":false,"given":"Kerollos","family":"Abdelsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3293-9261","authenticated-orcid":false,"given":"Kadir","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0758-3539","authenticated-orcid":false,"given":"Osama","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"25","key":"10375_CR1","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1161\/CIR.0000000000000937","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al (2020) 2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Circulation 142(25):e558\u2013e631. https:\/\/doi.org\/10.1161\/CIR.0000000000000937","journal-title":"Circulation"},{"issue":"7","key":"10375_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ (2018) Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med 379(7):655\u2013668. https:\/\/doi.org\/10.1056\/NEJMra1710575. PubMed PMID: 30110588","journal-title":"N Engl J Med"},{"issue":"12","key":"10375_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ (2015) New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy. J Am Coll Cardiol 65(12):1249\u20131254. https:\/\/doi.org\/10.1016\/j.jacc.2015.01.019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10375_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA et al (2022) Diagnosis and Evaluation of Hypertrophic Cardiomyopathy. J Am Coll Cardiol 79(4):372\u2013389. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.002","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10375_CR5","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1161\/CIRCULATIONAHA.119.040271","volume":"140","author":"A Weissler-Snir","year":"2019","unstructured":"Weissler-Snir A, Allan K, Cunningham K, Connelly KA, Lee DS, Spears DA et al (2019) Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario. Circulation 140(21):1706\u20131716. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040271","journal-title":"Circulation"},{"issue":"7","key":"10375_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E (2017) Hypertrophic Cardiomyopathy. Circ Res 121(7):749\u2013770. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311059","journal-title":"Circ Res"},{"issue":"3","key":"10375_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jacc.2009.05.006","volume":"54","author":"MS Maron","year":"2009","unstructured":"Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I et al (2009) Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance. J Am Coll Cardiol 54(3):220\u2013228. https:\/\/doi.org\/10.1016\/j.jacc.2009.05.006","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10375_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168407","volume":"11","author":"JA Stern","year":"2016","unstructured":"Stern JA, Markova S, Ueda Y, Kim JB, Pascoe PJ, Evanchik MJ et al (2016) A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy. PLoS ONE 11(12):e0168407. https:\/\/doi.org\/10.1371\/journal.pone.0168407","journal-title":"PLoS ONE"},{"issue":"11","key":"10375_CR9","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","volume":"66","author":"BJ Maron","year":"2015","unstructured":"Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA et al (2015) Low Operative Mortality Achieved With Surgical Septal Myectomy. J Am Coll Cardiol 66(11):1307\u20131308. https:\/\/doi.org\/10.1016\/j.jacc.2015.06.1333","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10375_CR10","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.jtcvs.2018.11.148","volume":"157","author":"K Hodges","year":"2019","unstructured":"Hodges K, Rivas CG, Aguilera J, Borden R, Alashi A, Blackstone EH et al (2019) Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. J Thorac Cardiovasc Surg 157(6):2289\u20132299. https:\/\/doi.org\/10.1016\/j.jtcvs.2018.11.148","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"17","key":"10375_CR11","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jacc.2022.02.032","volume":"79","author":"H Cui","year":"2022","unstructured":"Cui H, Schaff HV, Wang S, Lahr BD, Rowin EJ, Rastegar H et al (2022) Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 79(17):1647\u20131655. https:\/\/doi.org\/10.1016\/j.jacc.2022.02.032","journal-title":"J Am Coll Cardiol"},{"key":"10375_CR12","unstructured":"FDA Update: Mavacamten Approved For Obstructive HCM (2022) Am Colle Cardiol\u00a0"},{"issue":"6273","key":"10375_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC et al (2016) A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351(6273):617\u2013621. https:\/\/doi.org\/10.1126\/science.aad3456","journal-title":"Science"},{"issue":"21","key":"10375_CR14","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"CY Ho","year":"2020","unstructured":"Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM et al (2020) Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 75(21):2649\u20132660. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.064","journal-title":"J Am Coll Cardiol"},{"issue":"10253","key":"10375_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396(10253):759\u2013769. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X","journal-title":"The Lancet"},{"issue":"2","key":"10375_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG et al (2022) Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. J Am Coll Cardiol 80(2):95\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.048","journal-title":"J Am Coll Cardiol"},{"key":"10375_CR17","doi-asserted-by":"publisher","unstructured":"Tian Z, Li L, Li X, Wang Ja, Zhang Q, Li Z et al (2023) Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial. JAMA Cardiology.\u00a0https:\/\/doi.org\/10.1001\/jamacardio.2023.3030","DOI":"10.1001\/jamacardio.2023.3030"},{"key":"10375_CR18","unstructured":"Front Matter (2008) Cochrane Handbook for Systematic Reviews of Interventions. i-xxi"},{"issue":"7","key":"10375_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"10375_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"10375_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"7521","key":"10375_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/bmj.331.7521.903","volume":"331","author":"DG Altman","year":"2005","unstructured":"Altman DG, Bland JM (2005) Standard deviations and standard errors. BMJ 331(7521):903. https:\/\/doi.org\/10.1136\/bmj.331.7521.903","journal-title":"BMJ"},{"issue":"11","key":"10375_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"SB Heitner","year":"2019","unstructured":"Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D et al (2019) Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy. Ann Intern Med 170(11):741\u2013748. https:\/\/doi.org\/10.7326\/M18-3016","journal-title":"Ann Intern Med"},{"issue":"7","key":"10375_CR24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s44161-022-00093-x","volume":"1","author":"AC Chin","year":"2022","unstructured":"Chin AC, Day SM (2022) Myosin modulators move forward with FDA approval of mavacamten. Nature Cardiovascular Research 1(7):595\u2013596. https:\/\/doi.org\/10.1038\/s44161-022-00093-x","journal-title":"Nature Cardiovascular Research"},{"issue":"11","key":"10375_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","volume":"147","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Geske JB, Wolski K, Saberi S, Wang A et al (2023) Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks. Circulation 147(11):850\u2013863. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062534","journal-title":"Circulation"},{"key":"10375_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3342","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A et al (2023) Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial. JAMA Cardiology. https:\/\/doi.org\/10.1001\/jamacardio.2023.3342","journal-title":"JAMA Cardiology"},{"issue":"14","key":"10375_CR27","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jacc.2013.03.055","volume":"62","author":"T Kubo","year":"2013","unstructured":"Kubo T, Kitaoka H, Yamanaka S, Hirota T, Baba Y, Hayashi K et al (2013) Significance of High-Sensitivity Cardiac Troponin T in Hypertrophic Cardiomyopathy. J Am Coll Cardiol 62(14):1252\u20131259. https:\/\/doi.org\/10.1016\/j.jacc.2013.03.055","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10375_CR28","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","volume":"61","author":"JB Geske","year":"2013","unstructured":"Geske JB, McKie PM, Ommen SR, Sorajja P (2013) B-Type Natriuretic Peptide and Survival in Hypertrophic Cardiomyopathy. J Am Coll Cardiol 61(24):2456\u20132460. https:\/\/doi.org\/10.1016\/j.jacc.2013.04.004","journal-title":"J Am Coll Cardiol"},{"key":"10375_CR29","doi-asserted-by":"publisher","unstructured":"Correction to: Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning. Circulation. 0(0):CIR.0000000000001053. https:\/\/doi.org\/10.1161\/CIR.0000000000001053","DOI":"10.1161\/CIR.0000000000001053"},{"issue":"2","key":"10375_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1164\/rccm.167.2.211","volume":"167","author":"RMBK Ross","year":"2003","unstructured":"Ross RMBK, Casaburi R, Johnson BD, Marciniuk DD, Wagner PD et al (2003) ATS\/ACCP Statement on Cardiopulmonary Exercise Testing. Am J Respir Crit Care Med 167(2):211\u2013277. https:\/\/doi.org\/10.1164\/rccm.167.2.211. PubMed PMID: 12524257","journal-title":"Am J Respir Crit Care Med"},{"key":"10375_CR31","doi-asserted-by":"publisher","unstructured":"Rabiee Rad M, Ghasempour Dabaghi G, Habibi D (2023) Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials. Egypt Heart J 75(1):4. Epub 20230112. https:\/\/doi.org\/10.1186\/s43044-023-00328-7. PubMed PMID: 36633717; PubMed Central PMCID: PMCPMC9837360","DOI":"10.1186\/s43044-023-00328-7"},{"key":"10375_CR32","doi-asserted-by":"publisher","unstructured":"Ismayl M, Abbasi MA, Marar R, Geske JB, Gersh BJ, Anavekar NS (2023) Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Curr Probl Cardiol 48(1):101429. Epub 20220924.\u00a0https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101429. PubMed PMID: 36167226","DOI":"10.1016\/j.cpcardiol.2022.101429"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10375-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-023-10375-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10375-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T12:18:13Z","timestamp":1710764293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-023-10375-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["10375"],"URL":"https:\/\/doi.org\/10.1007\/s10741-023-10375-6","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"26 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}